Full Press Release Details
| FOR MORE INFORMATION: | Company Contact: |
| Jacqueline Lemke | |
| President, CEO and CFO | |
| Phone: 765.497.5829 | |
| jlemke@BASinc.com | |
| Agency Contact: | |
| Neil Berkman | |
| Berkman Associates | |
| Phone: 310.477.3118 | |
| info@berkmanassociates.com |
BASi Reports First Quarter
IN -- February 13, 2014 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the first
quarter of fiscal 2014.
the first quarter of the new fiscal year, revenue increased 7.2%, gross margin increased 15.6%, operating income increased 53.0%,
and net income excluding the impact of the change in warrant liability increased 115% compared to the first quarter of fiscal 2013.
BASi also generated $1,036,000 in cash from operations, and we paid down $1,247,000 on our line of credit while meeting all of
our other obligations. We paid off the remaining balance on our line of credit last month, and are currently pursuing alternatives
to replace it on better terms," said President & CEO and CFO Jacqueline Lemke.
are pleased by these results but not satisfied. In fiscal 2014 we plan to leverage our business model, using our existing capacity
and an incremental investment in people and skills to support the long-term growth we believe BASi is capable of delivering. To
achieve our goals, we remain focused on growing revenues even as we push ahead with our initiatives to control costs and improve
decision last year to concentrate our marketing programs on BASi's established strengths in specialty assay and drug discovery,
regulatory excellence, and our market-changing Culex NxT automated sampling system is paying dividends. With our expanded
sales team gaining traction in the marketplace, we are optimistic that the increase in new order bookings we have enjoyed in recent
months will continue.
celebrates its 40th anniversary in 2014, a milestone made all the more significant by the progress we have made these
past couple of years in strengthening the Company for the future. We are confident that we are pursuing the right strategy to enhance
operating performance and build value for our shareholders," Lemke said.
First Quarter Results
months ended December 31, 2013, revenue increased 7.2% to $6,220,000 compared to $5,803,000 for the first quarter of fiscal 2013.
Gross profit was $2,145,000, or 34.5% of revenue, compared to $1,855,000, or 32.0% of revenue, a year earlier. Operating expenses
for the first quarter of fiscal 2014 increased to $1,683,000 compared to $1,553,000 a year earlier, primarily due to planned increases
in selling and R&D expenses. Operating income for the first quarter of fiscal 2014 increased 53% to $462,000, compared to $302,000
net loss for the first quarter of fiscal 2014 was $662,000, or $0.09 per basic share and diluted share, which included a
non-cash increase in the fair value of warrant liability of $961,000. Excluding this charge, non-GAAP net income for the
first quarter of fiscal 2014 was $299,000, or $0.04 per basic and diluted share. For the first quarter of fiscal 2013, net
income was $256,000, or $0.03 per basic and diluted share, which included a non-cash decrease in the fair value of warrant
liability of $117,000. Excluding this benefit, non-GAAP net income for the first quarter of fiscal 2013 was $139,000, or
$0.02 per basic and diluted share.
for the first quarter of fiscal 2014 increased 5.3% to $4,916,000 from $4,670,000 for the first quarter of fiscal 2013, reflecting
an increase in new order bookings that began in recent months.
increased 15.1% to $1,304,000 versus $1,133,000 for the prior year's first quarter, primarily due to higher sales of Culex automated
the first quarter of fiscal 2014 was $912,000 compared to EBITDA of $851,000 for the first quarter of fiscal 2013.
Earnings Conference Call
scheduled a conference call at 11:00 a.m. EDT this morning to discuss its results for the quarter. To participate in the call,
dial 866.825.1709, passcode #95235310 at least five minutes before the start of the call. A simultaneous webcast may be accessed
from the Investors tab at www.BASInc.com. The webcast will be available for replay after 2:00 p.m. EST at this same Internet address.
For a telephone replay, dial 888.286.8010, passcode #65530693 after 2:00 p.m. EST.
Non-GAAP to GAAP Reconciliation
release contains financial measures that are not calculated in accordance with accounting principles generally accepted in the
United States (GAAP). The non-GAAP financial measures are net income excluding the income or expense of the change in warrant liability,
and EBITDA for the first quarters of fiscal 2014 and 2013. EBITDA refers to financial performance measures that exclude certain
income statement line items, such as interest, taxes, depreciation, and amortization and/or exclude certain non-cash or one-time
expenses as permitted by our credit agreements, such as stock-based compensation and the income or expense from the change in the
financial information should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated
in accordance with GAAP. Management, however, believes that these non-GAAP financial measures, when used in conjunction with the
results presented in accordance with GAAP, may provide a more complete understanding of the Company's results and may facilitate
a fuller analysis of the Company's results, particularly in evaluating performance from one period to another. Management has chosen
to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional
analyses of results and to illustrate the results giving effect to the non-GAAP adjustments shown in the reconciliation. Management
strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety
and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies,
even when similar terms are used to identify such measures.
About Bioanalytical Systems,
a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug
development companies and medical research organizations. The company focuses on developing innovative services and products that
increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties
related to changes in the market and demand for our products and services, the development, marketing and sales of products and
services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in
the company's filings with the Securities and Exchange Commission.
FOR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BIOANALYTICAL SYSTEMS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except per share amounts)(Unaudited)
| Three Months Ended | ||||||||
| December 31, | ||||||||
| 2013 | 2012 | |||||||
| Service revenue | $ | 4,916 | $ | 4,670 | ||||
| Product revenue | 1,304 | 1,133 | ||||||
| Total revenue | 6,220 | 5,803 | ||||||
| Cost of service revenue | 3,323 | 3,382 | ||||||
| Cost of product revenue | 752 | 566 | ||||||
| Total cost of revenue | 4,075 | 3,948 | ||||||
| Gross profit | 2,145 | 1,855 | ||||||
| Operating expenses: | ||||||||
| Selling | 437 | 370 | ||||||
| Research and development | 143 | 85 | ||||||
| General and administrative | 1,103 | 1,098 | ||||||
| Total operating expenses | 1,683 | 1,553 | ||||||
| Operating income | 462 | 302 | ||||||
| Interest expense | (164 | ) | (165 | ) | ||||
| Change in fair value of warrant liability - (increase) decrease | (961 | ) | 117 | |||||
| Other income | 1 | 2 | ||||||
| Income (loss) before income taxes | (662 | ) | 256 | |||||
| Income taxes | -- | -- | ||||||
| Net income (loss) | $ | (662 | ) | $ | 256 | |||
| Other comprehensive income (loss): | ||||||||
| Foreign currency translation adjustment | (26 | ) | 8 | |||||
| Comprehensive income (loss) | $ | (688 | ) | $ | 264 | |||
| Net Earning (Loss) per share | ||||||||
| Basic | $ | (0.09 | ) | $ | 0.03 | |||
| Diluted | $ | (0.09 | ) | $ | 0.03 | |||
| Weighted common shares outstanding: | ||||||||
| Basic | 7,735 | 7,639 | ||||||
| Diluted | 7,735 | 8,406 |
BIOANALYTICAL SYSTEMS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
| December 31, | September 30, | |||||||
| 2013 | 2013 | |||||||
| Assets | (Unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 841 | $ | 1,304 | ||||
| Accounts receivable | ||||||||
| Trade | 2,396 | 3,621 | ||||||
| Unbilled revenues and other | 977 | 691 | ||||||
| Inventories | 1,451 | 1,379 | ||||||
| Prepaid expenses | 407 | 238 | ||||||
| Total current assets | 6,072 | 7,233 | ||||||
| Property and equipment, net | 16,564 | 16,913 | ||||||
| Goodwill | 1,383 | 1,383 | ||||||
| Debt issue costs | 55 | 21 | ||||||
| Other assets | 45 | 47 | ||||||
| Total assets | $ | 24,119 | $ | 25,597 | ||||
| Liabilities and shareholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,215 | $ | 3,584 | ||||
| Accrued expenses | 1,538 | 1,689 | ||||||
| Customer advances | 2,891 | 2,815 | ||||||
| Income tax accruals | 16 | 30 | ||||||
| Revolving line of credit | 168 | 1,415 | ||||||
| Fair value of warrant liability | 1,573 | 612 | ||||||
| Current portion of capital lease obligation | 272 | 268 | ||||||
| Current portion of long-term debt | 5,205 | 613 | ||||||
| Total current liabilities | 14,878 | 11,026 | ||||||
| Capital lease obligation, less current portion | 401 | 471 | ||||||
| Long-term debt, less current portion | -- | 4,641 | ||||||
| Total liabilities | 15,279 | 16,138 | ||||||
| Shareholders ' equity: | ||||||||
| Preferred shares, authorized 1,000,000 shares, no par value: 1,185 | ||||||||
| Series A shares at $1,000 stated value issued and outstanding | ||||||||
| at December 31, 2013 and 1,335 at September 30, 2013 | 1,185 | 1,335 | ||||||
| Common shares, no par value: Authorized 19,000,000 | ||||||||
| shares; 7,885,229 issued and outstanding at December | ||||||||
| 31, 2013 and 7,703,891 at September 30, 2013 | 1,933 | 1,887 | ||||||
| Additional paid-in capital | 20,098 | 19,925 | ||||||
| Accumulated deficit | (14,382 | ) | (13,720 | ) | ||||
| Accumulated other comprehensive income | 6 | 32 | ||||||
| Total shareholders ' equity | 8,840 | 9,459 | ||||||
| Total liabilities and shareholders' equity | $ | 24,119 | $ | 25,597 |
BIOANALYTICAL SYSTEMS, INC.
RECONCILIATION OF GAAP TO NONGAAP EARNINGS
(In thousands) (Unaudited)
| Three Months Ended | ||||||||
| December 31, | ||||||||
| 2013 | 2012 | |||||||
| GAAP Net income (loss) | $ | (662 | ) | $ | 256 | |||
| Addback: | ||||||||
| Interest expense | 164 | 165 | ||||||
| Income taxes | -- | -- | ||||||
| Depreciation and amortization | 402 | 473 | ||||||
| Change in fair value | ||||||||
| of warrant liability - increase (decrease) | 961 | (117 | ) | |||||
| Stock option expense | 47 | 74 | ||||||
| NONGAAP EBITDA | $ | 912 | $ | 851 |
EBITDA - Earnings before interest, taxes, depreciation, amortization, stock option expenses and
the change in the fair value of warrant liability.